

Emetic Potential of Oral Chemo Agents

High: >90% risk; Moderate to High: ≥30% risk; Moderate: 30%-90%;
 Minimal to Low: <30% risk; Low: 10%-30%; Minimal: <10%

Drug	NCCN ¹	ASCO ²	MASCC/ESMO ³
abemaciclib	min-low	mod-high	--
abiraterone	min-low		--
acalabrutinib	min-low		--
adagrasib	mod-high		--
afatinib	min-low		low
alectinib	min-low		--
alpelisib	min-low		--
anastrozole	min-low		--
apalutamide	min-low		--
asciminib	min-low		--
avapritinib	mod-high		--
axitinib	min-low		low
azacitidine	mod-high		--
belzutifan	min-low		--
bexarotene	min-low		--
bicalutamide	min-low		--
binimetinib	mod-high		--
bosutinib	>400 mg/day: mod-high ≤400 mg/day: min-low	mod-high	mod
brigatinib	min-low		--

Drug	NCCN ¹	ASCO ²	MASCC/ESMO ³
busulfan	≥4 mg/day: mod-high <4 mg/day: min-low		--
cabozantinib (Cabometyx , Cometriq)		mod-high	--
capecitabine		min-low	low
capmatinib	min-low		--
ceritinib		mod-high	mod
chlorambucil		min-low	min
cobimetinib		min-low	--
crizotinib		mod-high	mod
cyclophosphamide	≥100 mg/m ² / day: mod-high <100 mg/m ² / day: min-low	mod-high	mod
dabrafenib	mod-high	min-low	low
dacomitinib		min-low	--
darolutamide	min-low		--
dasatinib		min-low	low
decitabine/cedazuridine	min-low		--
duvelisib		min-low	--
elacestrant	mod-high		--
enasidenib		mod-high	--
encorafenib	mod-high	min-low	--
entrectinib		min-low	--
enzalutamide	min-low		--
erdafitinib		min-low	--

Drug	NCCN ¹	ASCO ²	MASCC/ESMO ³
erlotinib	min-low		min
estramustine	mod-high	min-low	--
etoposide	mod-high	min-low	low
everolimus	min-low		low
exemestane	min-low		--
fedratinib	mod-high		--
fludarabine	min-low		low
flutamide	min-low		--
futibatinib	min-low		--
gefitinib	min-low		min
gilteritinib	min-low		--
glasdegib	min-low		--
hydroxyurea	min-low		min
ibrutinib	min-low		low
idelalisib	min-low		low
imatinib	>400 mg/day: mod-high ≤400 mg/day: min-low	mod-high	mod
ivosidenib	min-low		--
ixazomib	min-low		--
lapatinib	min-low		low
larotrectinib	min-low		--
lenalidomide	min-low		low
lenvatinib	>12 mg/day: mod-high ≤12 mg/day: min-low	mod-high	--
letrozole	min-low		--
lomustine	mod-high		--

Drug	NCCN ¹	ASCO ²	MASCC/ESMO ³
lorlatinib	min-low		--
megestrol	min-low		--
melphalan	min-low		min
mercaptopurine	min-low	--	
methotrexate	min-low		min
midostaurin	mod-high		--
mitotane	mod-high		--
momelotinib	min-low		--
neratinib	min-low		--
nilotinib	min-low		low
nilutamide	min-low		--
niraparib	mod-high		--
olaparib	mod-high	min-low	low
olutasidenib	min-low		
osimertinib	min-low		--
pacritinib	min-low		--
palbociclib	min-low		--
panobinostat	--	min-low	--
pazopanib	min-low		low
pemigatinib	min-low		--
pexidartinib	min-low		--
pirtobrutinib	min-low		--
pomalidomide	min-low		min
ponatinib	min-low		low
pralsetinib	min-low		--
procarbazine	mod-high		high
regorafenib	min-low		low
relugolix	min-low		--
repotrectinib	min-low		--
ribociclib	min-low	mod-high	--
ripretinib	min-low		--
rucaparib	mod-high		--
ruxolitinib	min-low		min
selinexor	mod-high		--
selpercatinib	min-low		--
sonidegib	min-low		--

Drug	NCCN ¹	ASCO ²	MASCC/ESMO ³
sorafenib	min-low		min
sotorasib	min-low		--
sunitinib	min-low		low
talazoparib	min-low		--
tamoxifen	min-low		--
tazemetostat	min-low		--
tegafur-uracil NUS	--	min-low	low
temozolomide	>75 mg/m ² /day: mod-high ≤75 mg/m ² /day: min-low ⁴	mod-high	mod
tepotinib	min-low		--
thalidomide	min-low		low
thioguanine	min-low		min
tivozanib	min-low		--
topotecan	min-low		--
toremifene	min-low		--
trametinib	min-low		--
tretinoin	min-low		--
trifluridine/tipiracil	min-low	mod-high	--
tucatinib	min-low		--
vandetanib	min-low		low
vemurafenib	min-low		min
venetoclax	min-low		--
vismodegib	min-low		min
vorinostat	min-low		low
zanubrutinib	min-low		--

¹ NCCN 2023. National Comprehensive Cancer Network. Antiemesis (Version 1.2024). December 13, 2023. [Accessed December 29, 2023](#)

- For some mod to high emetic risk agents, factors related to dosing (particularly continuous dosing for prolonged periods) and clinical experience suggest routine

premedication is *not* required. Individualized approach is appropriate for whether to premedicate each dose or prescribe antiemetics.

² **ASCO 2020.** Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. *J Clin Oncol.* 2020. Aug 20;38(24):2782-2797. [PDF](#)

³ **MASCC/ESMO 2016/2019.** Aapro M, et al. 2016 MASCC/ESMO Antiemetic Guideline 2016 With Updates in 2019. Multinational Association of Supportive Care in Cancer. Updated September 2019. Accessed August 25, 2020.

⁴ **NCCN 2023.** Temozolomide ≤ 75 mg/m²/day should be considered moderately emetogenic w/ concurrent radio-tx.